Eli Lilly and Company · 1 week ago
Director - Immunology Research
San Francisco, CA
Full-time
Onsite
Lead/Staff, Director/Executive
$164K/yr - $282K/yr
5+ years expEli Lilly and Company is a global healthcare leader dedicated to advancing therapies that extend healthspan and combat age-related diseases. They are seeking a highly motivated scientist to spearhead efforts focused on immune aging and rejuvenation, driving cutting-edge research to identify and develop novel interventions to restore immune homeostasis and improve organ function.
BiotechnologyHealth CareMedicalPharmaceutical
Responsibilities
Design and execute preclinical studies to investigate mechanisms underlying immune senescence, including but not limited to age-related hematopoietic stem cell (HSC) dysfunction, telomere attrition, senescence-associated phenotypes, and T-cell exhaustion
Develop rejuvenation/reprogramming strategies to revitalize hemopoietic and non-immune, parenchymal cells of interest in immune and age-related disorders
Utilize advanced techniques in cytometry, ‘omics and hi-dimensional datasets to identify targetable nodes for intervention. Use appropriate in vitro, in vivo and ex vivo models to assess immune aging phenotypes of interest
Collaborate with stakeholders in Immunology and other therapeutic areas to cross-functionally lead and develop research findings into future clinical candidates
Prepare and present research findings at internal meetings, scientific conferences, and in peer-reviewed publications
Stay abreast of emerging advances in the field to inform strategic decisions and help assess external opportunities as needed
Contribute to IP filings, and regulatory documentation as needed
Recruit and train a small team to scale research efforts
Qualification
Required
PhD in Immunology, Cell Biology, Developmental Biology, or a related field; Postdoctoral experience in aging biology or rejuvenation is required
5+ years of hands-on research experience in academia, biotech, or pharma, with a proven track record related to immune aging/senescence research
Preferred
Demonstrated expertise in molecular mechanisms of immune senescence, including inflammaging, stem cell exhaustion, and therapeutic interventions
Familiarity with landscape of immune aging research activities including but not limited to academic labs, biotechnology companies, and large pharma
Strong publication record in high-impact journals with first- or senior-author contributions
Proficiency in experimental design, data analysis and statistical methods
Excellent communication skills, with the ability to convey complex scientific concepts to diverse audiences
Experience with in vivo models of aging (e.g., progeroid mice, humanized models) and translational strategies for rejuvenation therapies
Advanced knowledge of stem cell rejuvenation techniques, epigenetic reprogramming and delivery systems
Prior experience leading a cross-functional team and/or managing others
Understanding of the unique regulatory hurdles in regeneration and aging-related therapeutics
Benefits
Company-sponsored 401(k)
Pension
Vacation benefits
Eligibility for medical, dental, vision and prescription drug benefits
Flexible benefits (e.g., healthcare and/or dependent day care flexible spending accounts)
Life insurance and death benefits
Certain time off and leave of absence benefits
Well-being benefits (e.g., employee assistance program, fitness benefits, and employee clubs and activities)
Company
Eli Lilly and Company
We're a medicine company turning science into healing to make life better for people around the world.
10001+ employees
H1B Sponsorship
Eli Lilly and Company has a track record of offering H1B sponsorships. Please note that this does not
guarantee sponsorship for this specific role. Below presents additional info for your
reference. (Data Powered by US Department of Labor)
Distribution of Different Job Fields Receiving Sponsorship
Represents job field similar to this job
Trends of Total Sponsorships
2025 (514)
2024 (236)
2023 (167)
2022 (133)
2021 (57)
2020 (52)
Funding
Current Stage
Public CompanyTotal Funding
$6.5M2024-02-12Post Ipo Debt· $6.5M
1978-01-13IPO
Leadership Team
David Ricks
Chair, CEO
Lucas Montarce
Executive Vice President and Chief Financial Officer
Recent News
The Motley Fool
2026-01-25
2026-01-24
2026-01-23
Company data provided by crunchbase